Bioabsorbable medical device with coating
A biodegradable, bioabsorbable medical device with a coating for capturing progenitor endothelial cells in vivo and delivering a therapeutic agent at the site of implantation. The coating on the medical device is provided with a bioabsorbable polymer composition such as a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive for controlling the rate of delivery of the therapeutic agent.
1. An expandable stent, comprising bioabsorbable polymer scaffold and a coating, wherein the expandable stent comprises a plurality of first meandering strut patterns forming an interconnected mesh, and at least one second strut pattern comprising a hoop circumferential about the longitudinal axis of the expandable stent, wherein the second strut pattern crystallizes when the stent is expanded, the bioabsorbable polymer scaffold comprising, at least about 70% (w/w) of a base polymer comprising a poly (L-lactide) moiety, and/or a poly (D-lactide) moiety, and/or poly L-lactide-co-PEG moiety, and/or poly D-lactide-co PEG moiety, linked with a modifying polymer comprising poly (L-lactide-co-Tri-methylene-carbonate) or poly (D-lactide-co-tri-methylene-carbonate) or poly (L-lactide-co-ε-caprolactone) or poly (D-lactide-co-ε-caprolactone), wherein the coating comprises a ligand specific to an progenitor endothelial cell surface antigen selected from the group consisting of CD34 CD45, CD133, CD14, CDw90, CD117, HLA-DR, VEGFR-1, VEGFR-2, CD146, CD130, CD131, stem cell antigen, stem cell factor 1, Tie-2, MCH-H-2Kk and MCH-HLA-DR.
2. The expandable stent of claim 1 , wherein the second strut pattern further comprises a through-void.
3. The expandable stent of claim 1 , wherein the ligand is configured to bind target cells in vivo.
4. The expandable stent of claim 1 , wherein the coating further comprises a bioabsorbable matrix.
5. The expandable stent of claim 4 , wherein the bioabsorbable matrix comprises at least one of the group consisting of: dextran, tropoelastin, elastin, laminin, fibronectin, fibrin, collagen, basement membrane proteins, and cross-linked tropoelastin.
6. The expandable stent of claim 1 , further comprising a pharmacological substance.
7. The expandable stent of claim 6 , wherein the pharmacological substance is at least one of the group consisting of: cyclosporin A, mycophenolic acid, mycophenolate mofetil acid, rapamycin, rapamycin derivatives, biolimus A9, CCI-779, RAD 001, AP23573, azathioprene, pimecrolimus, tacrolimus (FK506), tranilast, dexamethasone, corticosteroid, everolimus, retinoic acid, vitamin E, rosglitazone, simvastatins, fluvastatin, estrogen, 17β-estradiol, hydrocortisone, acetaminophen, ibuprofen, naproxen, fluticasone, clobetasol, adalimumab, sulindac, dihydroepiandrosterone, testosterone, puerarin, platelet factor 4, basic fibroblast growth factor, fibronectin, butyric acid, butyric acid derivatives, paclitaxel, paclitaxel derivatives, LBM-642, deforolimus, and probucol.
8. The expandable stent of claim 6 , wherein the stent is a drug-eluting stent.